research @ rice

University opens its newest, largest campus research facility in Houston

The 250,000-square-foot building is the new home for four key research areas at Rice: advanced materials, quantum science and computing, urban research and innovation, and the energy transition. Photo courtesy of Rice

As the academic year officially kicks off, professors have started moving in and Rice University has opened its largest core campus research facility, The Ralph S. O’Connor Building for Engineering and Science.

The 250,000-square-foot building is the new home for four key research areas at Rice: advanced materials, quantum science and computing, urban research and innovation, and the energy transition. The university aims for the space to foster collaboration and innovation between the disciplines.

"To me it really speaks to where Rice wants to go as we grow our research endeavors on campus," Michael Wong, Chair of the Department of Chemical and Biomolecular Engineering, whose lab is located in the new facility, said in a video from Rice. "It has to be a mix of engineering and science to do great things. We don’t want to do good things, we want to do great things. And this building will allow us to do that."

At $152 million, the state-of-the-art facility features five floors of labs, classrooms and seminar rooms. Common spaces and a cafe encourage communication between departments, and the top level is home to a reception suite and outdoor terrace with views of the Houston skyline.

It replaces 1940s-era Abercrombie Engineering Laboratory on campus, which was demolished in 2021 to make way for the new facilities. The iconic sculpture "Energy" by Rice alumnus William McVey that was part of the original building was preserved with plans to incorporate it into the new space.

The new building will be dedicated to its namesake Ralph O'Connor on Sept. 14 in Rice's engineering quad at 3 p.m. O'Connor, a Johns Hopkins University grad, became a fan Rice when he moved to Houston to work in the energy industry in the 1950s.

The former president and CEO of the Highland Oil Company and founder of Ralph S. O’Connor & Associates left the university $57 million from his estate after he died in 2018. The gift was the largest donation from an estate in Rice's history and brought his donations to the university, including those to many buildings on campus and endowments and scholarships, to a total of $85 million.

“How fitting that this building will be named after Ralph O’Connor,” Rice President Reginald DesRoches said in a statement last summer. “He was a man who always looked to the future, and the future is what this new engineering and science building is all about. Discoveries made within those walls could transform the world. Anybody who knew Ralph O’Connor knows he would have loved that.”

The dedication event will be open to the public. It will feature remarks from DesRoches, as well as Rice Provost Amy Dittmar, Dean of the Wiess School of Natural Sciences Thomas Killian, Chair of the Rice Board of Trustees Robert Ladd and Dean of the George R. Brown School of Engineering Luay Nakhleh. A reception and tours of the new building will follow.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted